The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).
 
Koichi Goto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
 
Dong-Wan Kim
No Relationships to Disclose
 
Shun Lu
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Sanofi; Showa Yakuhin Kako; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis/Pfizer (Inst); Verastem (Inst); Yakult Pharmaceutical (Inst)
 
Jin-Ji Yang
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (I)
 
Myung-Ju Ahn
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
 
Toshiaki Takahashi
Speakers' Bureau - AstraZeneca Japan; Lilly Japan; Ono Pharmaceutical
 
Takeharu Yamanaka
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Allison Margaret Kemner
Employment - GlaxoSmithKline; OxOnc
Stock and Other Ownership Interests - GlaxoSmithKline
 
Debasish Roychowdhury
Employment - OxOnc
Leadership - Radius Health
Stock and Other Ownership Interests - ProNAi; Radius Health; Sanofi
Consulting or Advisory Role - Medivation (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Roche
 
Jolanda Paolini
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Keith D. Wilner
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)